Parallel Advisors’s C4 Therapeutics CCCC Stock Holding History

Parallel Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-106	Closed	-$5K	–	3103
2021 Q3	$5K	Buy	+106	New	+$4.54K	﹤0.01%	2335

Other funds holding CCCC

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Parallel Advisors's CCCC Position: Q4 2021 in Review

Parallel Advisors sold out of C4 Therapeutics (CCCC) in Q4 2021, closing a stake of 106 shares — an estimated $5K sold.

Parallel Advisors first reported a position in CCCC in Q3 2021 and held it in 1 quarter. The position peaked at $5K in Q3 2021. 119 funds tracked by Wall St. Rank hold CCCC as of Q4 2021.

Parallel Advisors reported no remaining C4 Therapeutics position as of Q4 2021 after selling out during the quarter.
Parallel Advisors sold 106 C4 Therapeutics shares in Q4 2021, an estimated $5K.
Parallel Advisors first reported a position in C4 Therapeutics in Q3 2021 and held it in 1 quarter.
Parallel Advisors's C4 Therapeutics position peaked at $5K in Q3 2021.
119 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2021.

Based on Parallel Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.